Prime Medicine, Inc.

SEC insider activity covers quarterly filings through June 30, 2026. Later filings are not included. Reported roles do not establish current employment or current holdings. SEC filing documents, sections and filing-text search cover filings dated January 1, 2000 onward. Earlier filings are deferred until after launch.

PRME

organization

SIC: 2836

SEC Insider

$163.0M

241 transactions

Summary

Prime Medicine, Inc. (PRME) is an organization.

Recent Insider Transactions

As filed, including amendments; not net cash flow or current holdings. Joint reports count once. Totals cover known values only.

Buys: $143.0MSales: $20.0M35 insiders

Date	Insider	Type	Value
2025-08-01	Joint reporting: CRANDELL KEITH; GILLIS STEVEN; Burow Kristina; ARCH Venture Fund X, L.P.; ARCH Venture Fund X Overage, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, LLC; ARCH Venture Partners X, L.P.	Buy	$10.0M
2025-08-01	Joint reporting: ARCH Venture Fund XII, L.P.; ARCH Venture Partners XII, LLC; ARCH Venture Partners XII, L.P.	Buy	$10.0M
2025-08-01	NELSEN ROBERT	Buy	$10.0M
2025-08-01	Joint reporting: Alphabet Inc.; GV 2021, L.P.; GV 2021 GP, L.L.C.; GV 2021 GP, L.P.	Buy	$5.0M
2026-06-05	Cahill Thomas	A	$0
2026-06-05	Chung Wendy	A	$0
2026-06-05	Foster-Cheek Kaye I	A	$0
2026-06-05	Kelly Michael Aaron	A	$0
2026-06-05	NELSEN ROBERT	A	$0
2026-06-05	Marrazzo Jeffrey D	A	$0
2026-06-05	Schenkein David P	A	$0
2026-04-16	Makhni Svetlana Ni(Chief Financial Officer)	A	$0
2026-02-26	Reine Allan(Chief Executive Officer)	A	$0
2026-02-23	Alenson Carman(See Remarks)	A	$0
2026-02-23	LEE ANN L.(Chief Technical Officer)	A	$0
2025-08-01	Alenson Carman(See Remarks)	D	—
2025-08-01	Alenson Carman(See Remarks)	A	—
2025-08-01	Alenson Carman(See Remarks)	D	—
2025-08-01	Alenson Carman(See Remarks)	A	—
2025-08-01	Alenson Carman(See Remarks)	D	—

SEC filings: SEC EDGAR

Activity data: SEC EDGAR

Prime Medicine, Inc. — Contributions, Lobbying & Contracts | Poliscope